Tamtam Try Tamtam free
QIAGEN logo

QIAGEN account plan

Sample to Insight solutions

At a glance

QIAGEN sells Sample to Insight molecular testing kits, instruments and bioinformatics; FY2025 net sales of $2,090.0 million.

QIAGEN N.V. is a Dutch holding company headquartered in Venlo, listed on the NYSE (QGEN) and in Frankfurt (QIA). It sells sample preparation, assays, instruments and bioinformatics software to more than 500,000 customers in Life Sciences (academia, pharma, forensics) and molecular diagnostics, delivering to more than 160 countries. In FY2025 net sales were $2,090.0 million (+6%), operating income $465.9 million (22.3% margin) and net income $424.9 million; consumables and related revenues made 90% of sales. It employed about 5,500 people as of 30 June 2026. Jonathan M. Pratt became CEO on 1 September 2026, succeeding Thierry Bernard.

Business units

Strategic priorities

Grow the five pillars to about $2 billion
Sample technologies, QuantiFERON, QIAstat-Dx, QIAcuity and QIAGEN Digital Insights made $1.5 billion, about 72% of 2025 sales, and are targeted at about $2 billion by 2028. Management expects them to grow about 7% in 2026.
Return to growth in the second half of 2026
The FY2026 outlook is net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 CER, with H2 growth of about 3-4% from launches and the end of NeuMoDx and Dialunox comparisons.
Automation and new instruments
QIAsymphony Connect and QIAsprint Connect are launched, QIAmini is due in H2 2026, and a fully automated QuantiFERON workflow with Diasorin and Inpeco is targeted for late 2027.
AI in bioinformatics and customer service
QIAGEN launched the QIA Agent AI laboratory assistant in May 2026 and a QDI collaboration with NVIDIA on graph-based AI for target identification and biomarker discovery.
Bring bloodstream infection panels to the U.S.
QIAstat-Dx BCID panels for bloodstream infections are launched in Europe; the first panel was submitted to the FDA in January 2026.
New CEO and strategic review
Jonathan M. Pratt took over as CEO on 1 September 2026 while the Supervisory Board continues a strategic review with independent advisors, with no timetable given.

Latest results

In Q2 2026 net sales were $535 million, unchanged on a reported and CER basis versus Q2 2025 and ahead of the outlook for an about 2% CER decline. The growth pillars grew about 5% CER while the rest of the portfolio fell 13% CER; instrument sales declined at a low-teens CER rate on cautious U.S. Life Sciences capital spending. Adjusted operating income margin was 29.4% (29.9% a year earlier) and adjusted diluted EPS $0.62. H1 2026 net sales were $1,027 million (+1%, -1% CER). In April 2026 QIAGEN had cut its FY2026 outlook from at least 5% CER sales growth to about 1-2% CER; that outlook was reaffirmed in August.

Investments and deals

Parse Biosciences acquisition
Acquired 2 December 2025 for $229.1 million: instrument-free single-cell RNA workflows with more than 3,000 customers; expected to exceed a 2026 sales target of about $40 million.
Genoox acquisition
Acquired 23 May 2025: a cloud-based AI platform for clinical genetic testing, integrated into QIAGEN Digital Insights.
Capex and IT
Capex for property, plant and equipment was $201.0 million in 2025 ($167.2 million in 2024), with a multi-year SAP S/4HANA implementation and cyber security investment under way.
Shareholder returns
A $496.7 million synthetic share repurchase completed in January 2026; a dividend of about $72 million paid in July 2026, up 40% per share.
Restructuring
The 2025 Restructuring Program relocates positions and consolidates functions to lower-cost locations, at a total cost of about $60.0 million, of which about $25.0 million expected in 2026.

Challenges and risks

Lower QuantiFERON immigration testing
Immigration testing is about 10% of QuantiFERON sales (about $50 million); QIAGEN cut about $35 million of it from its 2026 expectations and now sees QuantiFERON steady at around $500 million.
Cautious U.S. Life Sciences spending
About $40 million of 2026 caution from U.S. research customers, OEM ordering volatility and the Middle East conflict; instrument sales fell at a low-teens CER rate in Q2 2026.
Tariffs and China
The 20-F names U.S. tariffs and U.S.-China trade policy as risks; Asia Pacific, Japan and Rest of World sales fell 2% in 2025 on lower demand in China.
Research funding
Sales to universities and government labs depend on grants, particularly from the U.S. NIH; budget cuts could significantly hurt results.
Leadership transition
The CEO change and the open strategic review are flagged as risks to execution and retention.

What leadership says

“We achieved solid growth across key pillars, particularly Sample technologies, QIAcuity and QDI, while navigating continued pressure on instrument spending in the U.S.”

Thierry Bernard, former Chief Executive Officer · Q2 2026 results release, 5 August 2026

“My first priority will be to listen to QIAGEN teams and customers, learn more about the business and understand where we can sharpen our choices, strengthen execution and create greater impact.”

Jonathan M. Pratt, Chief Executive Officer · CEO appointment press release, 24 August 2026

“We increased the 2026 dividend by 40% compared with 2025 and continue to evaluate way to deploy capital to the highest-return opportunities.”

Roland Sackers, Chief Financial Officer · Q2 2026 results release, 5 August 2026

“AI is only as valuable as the scientific knowledge behind it.”

Thierry Bernard, former Chief Executive Officer · Q2 2026 results call, 6 August 2026

Where a supplier can help

Lower-cost operations under restructuring
The 2025 Restructuring Program consolidates functions in lower-cost locations; suppliers of shared services, automation or outsourcing can support that move.
IT, ERP and cyber security
The multi-year SAP S/4HANA implementation and cyber security investment create needs for integrators, security tools and data migration help.
Launch support for new instruments
With H2 2026 growth relying on QIAsymphony Connect, QIAsprint Connect, QIAmini and BCID panels, suppliers of components, field service, training and commercial enablement are relevant.
AI and knowledge-base tooling
The QIA Agent assistant and QDI work with NVIDIA point to demand for AI infrastructure, data curation and conversational commerce tooling.
A new CEO reviewing choices
Jonathan M. Pratt's stated aim to sharpen choices and strengthen execution, plus the strategic review, means supplier and portfolio decisions may be revisited.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like QIAGEN?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about QIAGEN

What does QIAGEN do?

QIAGEN sells Sample to Insight solutions: sample preparation kits, assays, instruments and bioinformatics software for Life Sciences research and molecular diagnostics, to more than 500,000 customers.

What is QIAGEN's revenue?

FY2025 net sales were $2,090.0 million, up 6%, with operating income of $465.9 million. H1 2026 net sales were $1,027 million.

How many employees does QIAGEN have?

About 5,500 employees as of 30 June 2026, across more than 35 locations.

Who leads QIAGEN?

Jonathan M. Pratt has been CEO since 1 September 2026, succeeding Thierry Bernard. Roland Sackers is CFO and Stephen H. Rusckowski chairs the Supervisory Board.

What is QIAGEN's strategy?

QIAGEN focuses on five growth pillars, targeted at about $2 billion of sales by 2028, and on solid profitable growth, while its Supervisory Board runs a strategic review.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)